News

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...
Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...
Eli LillyDemand for weight-loss drugs in India has shot up.And rivals Novo Nordisk and Eli Lilly are battling for market ...
Novo Nordisk (NVO) and Eli Lilly & Co. (NYSE:LLY), the global leaders in obesity medications, are now facing their first ...
Wall Street notched another record close on Thursday, as market participants snapped up equities and dumped bonds after nonfarm payrolls jumped more than expected in June. The S&P 500 Health Care ...
Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatments. They face supply chain challenges, but both stocks show strong ...
The demand for weight-loss medications is rapidly increasing in India, with competitors Eli Lilly and Novo Nordisk vying for ...
Novo Nordisk and Eli Lilly reported booming sales Thursday from the new generation of diabetes and weight-loss drugs they’ve pioneered, as both drugmakers continue to scramble to keep up with ...
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are the top two healthcare stocks in the world based on market cap. Their diabetes and weight loss medications are a big reason these have been ...
Eli Lilly hasn't grown earnings at nearly the same pace as Novo Nordisk, but expectations are extremely high. The stock currently trades for 45.7 times forward-looking earnings expectations.
Novo Nordisk and Eli Lilly are going to extraordinary lengths to secure the plants and machinery needed to churn out their popular appetite-suppressing drugs.